Anticoagulation therapy with heparin- and low-molecular-weight (LMW) heparins, used in thrombotic and vascular disorders, has reached an annual cost of nearly $ 4 billion for the drugs alone. Yet heparin usage suffers from several problems, including bleeding complications, that may prove fatal. Consensus is growing that LMW heparins also suffer from similar problems, although the frequency and severity of incidences may be lower. Fondaparinux, a heparin-based pentasaccharide, was introduced in 2001 to treat some thrombotic conditions. Preliminary indications are that this five-residue sequence may have bleeding problems. In addition, its synthesis is difficult and effort intensive. Heparin, LMW heparin and fondaparinux accelerate the inhibition of critical enzyme(s) of the clotting cascade by antithrombin, a plasma serine proteinase inhibitor. Advances made on the molecular mechanism of heparin activation of antithrombin by others and the PI led to the rational design of small, highly sulfated, synthetic, non-heparin organic antithrombin activators. These rationally designed molecules were the first small, organic molecules found to activate antithrombin. We have now advanced our rational approach by designing a second generation activators, including IQ3A67S-B345S, based on our earlier fundamental studies. Preliminary studies suggest that the second generation activator IQ3A67S-B345S binds and activates antithrombin ~9-fold better than the first generation activator. A patent application has been submitted for this activator and its derivatives. This proposal focuses on I) developing a high-yielding synthesis and purification method for the second generation activator and its derivatives; II) studying the interaction of the activator (and its structural analogs) with antithrombin at a molecular level; and III) testing the efficacy of the organic antithrombin activator (and its derivatives) in in vitro and ex vivo models of thrombosis. Our approach of computerized molecular design guided by mechanistic biochemical knowledge and ex vivo efficacy is a unique feature directing this work. The proposed work is critical for determining the organic activator to focus advanced phase II efforts.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Small Business Technology Transfer (STTR) Grants - Phase I (R41)
Project #
1R41HL081972-01
Application #
6990302
Study Section
Special Emphasis Panel (ZRG1-HEME-E (10))
Program Officer
Sarkar, Rita
Project Start
2005-09-01
Project End
2007-08-31
Budget Start
2005-09-01
Budget End
2007-08-31
Support Year
1
Fiscal Year
2005
Total Cost
$208,148
Indirect Cost
Name
Novelmed Therapeutics, Inc.
Department
Type
DUNS #
190155171
City
Twinsburg
State
OH
Country
United States
Zip Code
44106
Al-Horani, Rami A; Desai, Umesh R (2012) Electronically Rich N-Substituted Tetrahydroisoquinoline 3-Carboxylic Acid Esters: Concise Synthesis and Conformational Studies. Tetrahedron 68:2027-2040
Al-Horani, Rami A; Desai, Umesh R (2010) Chemical Sulfation of Small Molecules - Advances and Challenges. Tetrahedron 66:2907-2918
Henry, Brian L; Thakkar, Jay N; Martin, Erika J et al. (2009) Characterization of the plasma and blood anticoagulant potential of structurally and mechanistically novel oligomers of 4-hydroxycinnamic acids. Blood Coagul Fibrinolysis 20:27-34
Raghuraman, Arjun; Liang, Aiye; Krishnasamy, Chandravel et al. (2009) On designing non-saccharide, allosteric activators of antithrombin. Eur J Med Chem 44:2626-31
Henry, Brian L; Desai, Umesh R (2008) Recent research developments in the direct inhibition of coagulation proteinases--inhibitors of the initiation phase. Cardiovasc Hematol Agents Med Chem 6:323-36
Raghuraman, Arjun; Riaz, Muhammad; Hindle, Michael et al. (2007) Rapid and efficient microwave-assisted synthesis of highly sulfated organic scaffolds. Tetrahedron Lett 48:6754-6758
Henry, Brian L; Monien, Bernhard H; Bock, Paul E et al. (2007) A novel allosteric pathway of thrombin inhibition: Exosite II mediated potent inhibition of thrombin by chemo-enzymatic, sulfated dehydropolymers of 4-hydroxycinnamic acids. J Biol Chem 282:31891-9
Raghuraman, Arjun; Tiwari, Vaibhav; Zhao, Qian et al. (2007) Viral inhibition studies on sulfated lignin, a chemically modified biopolymer and a potential mimic of heparan sulfate. Biomacromolecules 8:1759-63
Rahman, Mohammed; Riaz, Muhammad; Desai, Umesh R (2007) Synthesis of biologically relevant biflavanoids--a review. Chem Biodivers 4:2495-527
Raghuraman, Arjun; Mosier, Philip D; Desai, Umesh R (2006) Finding a needle in a haystack: development of a combinatorial virtual screening approach for identifying high specificity heparin/heparan sulfate sequence(s). J Med Chem 49:3553-62

Showing the most recent 10 out of 11 publications